An Australian based medical device company, PolyNovo Limited (ASX:PNV) updated the market with its presentation to be presented at the Macquarie small and mid-cap virtual investor forum on 5 May 2020 and.
The Company discussed about its current products and first half outcomes in its investor’s presentation. The Current two products of the Company are- NovoSorb®BTM and NovoSorb® Syntrel.
The Cash on hand per March ASX announcement reported to be $7.4 million, and PNV received ascending revenues with the US in March.
Post announcement share price of PNV rose by 10.68% to $2.280 on 5 May 2020 (at AEST 12:18 AM).